Genetic predisposition to drug-induced hepatotoxicity
References (74)
- et al.
Acute and chronic drug-induced hepatitis
Clin Gastroenterol
(1988) - et al.
Formation of an inactive cytochrome P-450 Fe (II)-metabolite complex after administration of troleandomycin in humans
Biochem Pharmacol
(1982) - et al.
Isoniazid-rifampin fulminant hepatitis. A possible consequence of the enhancement of isoniazid hepatotoxicity by enzyme induction
Gastroenterology
(1977) - et al.
Effect of fasting on metabolite-mediated hepatotoxicity in the rat
Gastroenterology
(1979) - et al.
The genetic polymorphisms of debrisoquine/sparteine metabolism — Clinical aspects
Pharmacol Ther
(1990) - et al.
A proposed mechanism for chlorpromazine jaundice — defective hepatic sulphoxidation combined with rapid hydroxylation
J Hepatol
(1988) - et al.
Genetically determined oxidation polymorphism and drug hepatotoxicity. Study of 51 patients
J Hepatol
(1989) - et al.
Genetic polymorphism of S-mephenytoin hydroxylation
Pharmacol Ther
(1989) - et al.
Possible association between poor metabolism of mephenytoin and hepatotoxicity caused by AtriumR, a fixed combination preparation containing phenobarbital, febarbamate and difebarbamate
J Hepatol
(1994) - et al.
The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans
J Biol Chem
(1994)
Role of polymorphic and monomorphic human arylamine N-acetyl-transferases in determining sulfamethoxazole metabolism
Biochem Pharmacol
N-acetyltransferase polymorphism. Comparison of phenotype and genotype in humans
Biochem Pharmacol
The deficiency of sulphoxidation of S-carboxymethylcysteine
Pharmacol Ther
Regulation of gamma-glutamyl-cysteine synthetase by nonallosteric feedback inhibition by glutathione
J Biol Chem
Familial occurrence of hypersensitivity to phenytoin
Am J Med
Metabolic activation of the tricyclic antidepressant amineptine. I. Cytochrome P-450-mediated in vitro covalent binding
Biochem Pharmacol
Metabolic activation of the tricyclic antidepressant amineptine. II. Protective role of glutathione against in vitro and in vivo covalent binding
Biochem Pharmacol
Metabolic activation of the tricyclic antidepressant amineptine by human liver cytochrome P-450
Biochem Pharmacol
Possible role of HLA in hepatotoxicity. An exploratory study in 71 patients with drug-induced idiosyncratic hepatitis
J Hepatol
Mécanisme des hépatites médicamenteuses. Une conséquence de la superposition de deux systèmes xénophobes
Gastroenterol Clin Biol
Jaundice from troleandomycin and oral contraceptives
Ann Intern Med
Inhibition of rat liver estrogen 2/4-hydroxylase activity by troleandomycin: comparison with erythromycin and roxithromycin
J Pharmacol Exp Ther
Effects of pregnancy on the toxicity and metabolism of acetaminophen in mice
J Pharmacol Exp Ther
In vitro assessment of pharmacogenetic susceptibility to toxic drug metabolites in humans
Fed Proc
Pharmacogenetic phenotyping and genotyping. Present status and future potential
Clin Pharmacokinet
The P450 superfamily: update on new sequences, gene mapping, accession numbers, early trivial names of enzymes, and nomenclature
DNA Cell Biol
Polymorphic hydroxylation of debrisoquine in man
Lancet
Polymorphism of dextromethorphan oxidation in a French population
Br J Clin Pharmacol
Hydroxylation polymorphisms of debrisoquine and mephenytoin in European populations
Eur J Clin Pharmacol
Clinical significance of the sparteine/debrisoquine oxidation polymorphism
Eur J Clin Pharmacol
Impaired oxidation of debrisoquine in patients perhexiline liver injury
Gut
Effect of liver diseases on dextromethorphan oxidation capacity and phenotype. Study in 107 patients
Br J Clin Pharmacol
Impaired oxidation of debrisoquine in patients with perhexiline neuropathy
Br Med J
Genetic predisposition to drug hepatotoxicity. Role in hepatitis caused by amineptine, a tricyclic antidepressant
Hepatology
Cited by (94)
Pharmacogenomics, concepts for the future of perioperative medicine and pain management: A review
2020, Best Practice and Research: Clinical AnaesthesiologyCitation Excerpt :While MH is related to a specific functional mechanism in a calcium channel, halothane-induced hepatitis results from an immune response to metabolites produced by the cytochrome enzyme CYP2E1. This occurs in approximately 1 in 10,000 patients, and although the genetic mechanisms involved are not entirely clear, there is clear evidence that it is familial [34–36]. Physiological responses to inhalation anesthetics vary; however, genetic mutations often only affect these responses at anesthetic concentrations much higher than those usually used in mammals.
Hepatotoxicity of Dermatologic Drug Therapy
2020, Comprehensive Dermatologic Drug Therapy, Fourth Edition3D organotypic HepaRG cultures as in vitro model for acute and repeated dose toxicity studies
2014, Toxicology in VitroGlutathione metabolism modeling: A mechanism for liver drug-robustness and a new biomarker strategy
2013, Biochimica et Biophysica Acta - General SubjectsCitation Excerpt :This is illustrated by the observed association between polymorphisms in GCS, tissue glutathione concentrations and disease susceptibility in the human population [17–19]. However, it is important to note that other studies have identified only a limited correlation between liver injury and genetic polymorphisms in other enzymes of the glutathione pathway, or numerous drug metabolizing enzymes, and susceptibility to adverse drug reactions [20,21]. This could be due to a lack of influence of the affected enzymes on hepatic glutathione concentrations [22] or the complexity of the underlying mechanisms, which include many non-genetic factors [23].
Hepatotoxicity of psychotropic drugs and drugs of abuse
2013, Drug-Induced Liver DiseaseHepatotoxicity of dermatologic drug therapy
2012, Comprehensive Dermatologic Drug Therapy: Expert Consult - Online and Print